我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

坎地沙坦和苯那普利治疗高血压病的对照研究(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2007年第1期
页码:
67-69
栏目:
临床研究
出版日期:
2007-01-01

文章信息/Info

Title:
Comparative study of candesartan and benazepril in treatment of essential hypertension
作者:
刘培良; 陈瑶; 李轩; 石春来; 裴丽峰; 靖涛
辽宁省金秋医院心血管内科,辽宁 沈阳 110016
Author(s):
LIU Peiliang;  CHEN Yao;  LI Xuan;  SHI Chunlai;  PEI Lifeng;  JING Tao
Department of Cardiology, Jinqiu Hospital of Liaoning Province, Shenyang 110016, Liaoning,China
关键词:
坎地沙坦;  苯那普利; 高血压; 原发性
Keywords:
candesartan; benazepril; essential hypertension
分类号:
R544.1;R972
DOI:
-
文献标识码:
A
摘要:
目的 评价坎地沙坦同苯那普利治疗高血压病的疗效及其对血脂、肾功能的影响及副作用。方法 坎地沙坦组59例给予坎地沙坦剂量8～16 mg/d，苯那普利组56例服用苯那普利，剂量10~20 mg/d，均治疗6周。治疗前后所有参与者测血压和测定胆固醇、三酰甘油、肾功能。结果 监测血压显示坎地沙坦组降压与苯那普利组无差异，对胆固醇、三酰甘油没有影响，有降低尿酸的作用，与苯那普利组相比，咳嗽发生率低，并能改善肾功能及保护内皮细胞功能。结论 坎地沙坦同苯那普利治疗轻、中度高血压病安全、有效，对血脂、肾功能无影响。坎地沙坦有降低尿酸的作用，咳嗽发生率低。
Abstract:
AIM To compare the therapeutic effects of candesartan and benazepril in the treatment of essential hypertension. METHODS Fifty nine patients were treated with candesartan (8-16 mg/d) while fifty six patients were treated with benazepril (10-20 mg/d) for six weeks, and the results were compared. Blood pressure was monitored and blood lipid, urea nitrogen, creatinine, urine acid, blood α1MG and urine α1MG, urine Alb and plasma renin activity (PRA) were examined before and after the treatment. RESULTS Blood pressure monitoring showed no difference in the antihypertensive effect between the two drugs. Candesartan had no effect on TG and TC but it decreased the level of urine acid. The incidence of cough was lower in candesartan treated group. Candesartan also decreased blood α1MG and urine α1MG and urine Alb (P<0.01), while plasma renin activity (PRA) increased (P<0.01). CONCLUSION Candesartan is effective and safe in the treatment of hypertension and it can decrease the level of urine acid of blood. The incidence of cough is lower when candesartan is administrated.

参考文献/References

［1］张海英，李玉珍. 坎地沙坦的药理特性及在治疗高血压中的应用［J］. 临床药物治疗杂志，2004,2（1）:57-60.

［2］于力，裴兆辉. 血管紧张素Ⅱ受体拮抗剂在心血管疾病中的临床应用 ［J］，心脏杂志，2002,14(3)：266-267.

［3］周践，谭次娥，任浩洋. 抗高血压新药—血管紧张素Ⅱ受体拮抗剂坎地沙坦［J］， 药物与临床，2001，16（2）： 54-封三，53.

［4］江汀，张爱民,钟日钦,等. 长效与非长效抗高血压药物疗效比较［J］，心脏杂志，2001,13(3)：237-238.

［5］薛玉生，郑强荪， 张利华,等. 氯沙坦治疗轻、中度高血压病疗效评价［J］，心脏杂志，2000,12(4)：257-259.

［6］翁南星,吴奇志,郑东阳. 缬沙坦治疗轻、中度高血压病的疗效和安全性［J］，心脏杂志，2004,16(2):149-151

［7］Otsuka K,Tsukiyama H.Hemodynamic effects of MK954(loartan potassium),an angiotensin Ⅱ receptor antagonist,in patients with essential hypertension in Japanese［J］. Rinsho Iyaku,1995,11(1):165-174.

［8］Fauvel JP,Laville M,Maakel N,et al. Effects of losartan on renal hemodynamic parameters in hypertensives［J］. J Hypertens,1994,12 (Suppl 3):S93.

［9］Goldberg AI,Dunlay MC,Sweet CS.Safety and tolerability of losartan potassium,an angiotensin Ⅱreceptor antagonist,compared with hydrochlorothiazide,atenolol,felodipine ER,and angiotensincoverting enzyme inhibitors for the treatment of systemic hypertension［J］. Am J Cardiol,1995,75(12):793-795.

备注/Memo

备注/Memo:
收稿日期：2006-02-17.通讯作者： 刘培良,主任医师,主要从事心血管疾病诊治研究 Email: liupeiliang@medmail.com.cn
更新日期/Last Update: